Literature DB >> 14615682

[Problems of treating writer's cramp with botulinum toxin injections: results from 10 years of experience].

M-H Marion1, K Afors, M P Sheehy.   

Abstract

We studied the efficacy of botulinum toxin (BTX-A) injections in 167 patients, from a large cohort of 259 patients, presenting with writer's cramp (WC) and followed up to 10 years. The selection of the muscle was based on a careful physical examination, using up to 6 manoeuvres whilst attempting to write in order to bring out the original dystonic posture. The injection technique had to be precise, under EMG guidance, with a hollow recording needle to detect muscle or finger fascicle. The results showed a good efficacy and tolerance of this treatment in the long term with recovery of normal writing in 46 per cent, partial benefit in 10 per cent, failure in 21 per cent, and loss to follow-up after the first injection in 23 per cent. Among the responders, 27 per cent carried on the treatment every 9 months on average, with a duration of benefit of 6 months with follow-up between 3 and 9 years. Mirror dystonia had no prognostic value. Secondary dystonia, tremulous WC, long duration WC and progressive WC were associated with poor outcome.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615682

Source DB:  PubMed          Journal:  Rev Neurol (Paris)        ISSN: 0035-3787            Impact factor:   2.607


  12 in total

1.  Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up.

Authors:  J J M Kruisdijk; J H T M Koelman; B W Ongerboer de Visser; R J de Haan; J D Speelman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-21       Impact factor: 10.154

Review 2.  Evidence for the effectiveness of botulinum toxin for writer's cramp.

Authors:  K Dashtipour; R A Pender
Journal:  J Neural Transm (Vienna)       Date:  2008-03-06       Impact factor: 3.575

Review 3.  Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Authors:  Richard M Kostrzewa; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

4.  Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.

Authors:  Codrin Lungu; Barbara I Karp; Katharine Alter; Regina Zolbrod; Mark Hallett
Journal:  Mov Disord       Date:  2011-02-01       Impact factor: 10.338

Review 5.  Task-specific dystonias: a review.

Authors:  Diego Torres-Russotto; Joel S Perlmutter
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 6.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

Review 7.  Treatment of focal dystonias with botulinum neurotoxin.

Authors:  Mark Hallett; Reiner Benecke; Andrew Blitzer; Cynthia L Comella
Journal:  Toxicon       Date:  2008-12-13       Impact factor: 3.033

Review 8.  Treatment of focal hand dystonia: current status.

Authors:  Navnika Gupta; Sanjay Pandey
Journal:  Neurol Sci       Date:  2021-07-02       Impact factor: 3.307

9.  Treatment of focal dystonia.

Authors:  Amit Batla; Maria Stamelou; Kailash P Bhatia
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

10.  Mirror movements in movement disorders: a review.

Authors:  Benjamin C Cox; Massimo Cincotta; Alberto J Espay
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.